Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

Lantern Pharma Inc. (NASDAQ: LTRN) has announced the completion of targeted patient enrollment in Japan for its Phase 2 HARMONIC(TM) clinical trial, evaluating the investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients. This achievement, accomplished ahead of schedule, marks a pivotal moment in the company's efforts to address the unmet medical needs of never-smoker NSCLC patients, a group with limited treatment options. The trial enrolled 10 patients across five sites in Japan, including the prestigious National Cancer Center in Tokyo.

The selection of Japan as a strategic location for the trial is no coincidence, given the country's high incidence of never-smoker NSCLC cases. LP-300 is being tested in combination with standard chemotherapy agents, specifically targeting patients who have relapsed after tyrosine kinase inhibitor therapy. This approach underscores Lantern Pharma's commitment to leveraging its AI-driven platform to identify and accelerate the development of therapies for underserved cancer markets.

Additional trial data from Taiwan and the U.S. is anticipated later in the third quarter of 2025, which will further illuminate the potential of LP-300 in treating never-smoker NSCLC. Lantern Pharma's innovative use of artificial intelligence and machine learning in oncology drug development represents a forward-thinking approach to tackling complex cancer types. For more information on the trial, visit https://ibn.fm/JXFqG.

The completion of enrollment in Japan not only highlights Lantern Pharma's international strategy but also its dedication to improving outcomes for patients with limited treatment options. As the company awaits further data from its trials, the medical community watches closely, hopeful for breakthroughs in the treatment of never-smoker NSCLC.